Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

Background and Objective Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVV...

Full description

Saved in:
Bibliographic Details
Published in:Clinical drug investigation 2015-04, Vol.35 (4), p.275-280
Main Authors: McLaughlin, Milena M., Ammar, Abeer T., Gerzenshtein, Lana, Scarsi, Kimberly K.
Format: Article
Language:English
Subjects:
Adult
Drug Dosage Calculations
Female
Hemofiltration - methods
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Models, Statistical
Pharmacology/Toxicology
Pharmacotherapy
Reverse Transcriptase Inhibitors - administration & dosage
Short Communication
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Objective Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH. Methods A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH. Results A proposed table of dosing recommendations for NRTIs during CVVH is presented. Conclusion Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.
ISSN:1173-2563
1179-1918
DOI:10.1007/s40261-015-0275-9